ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial-Reference-Cited by-同舟云学术

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

Published:2018-05 Issue:5 Volume:19 Page:694-704
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Wrangle John M,Velcheti Vamsidhar,Patel Manish R,Garrett-Mayer Elizabeth,Hill Elizabeth G,Ravenel James G,Miller Jeffrey S,Farhad Mohammad,Anderton Kate,Lindsey Kathryn,Taffaro-Neskey Michele,Sherman Carol,Suriano Samantha,Swiderska-Syn Marzena,Sion Amy,Harris Joni,Edwards Andie R,Rytlewski Julie A,Sanders Catherine M,Yusko Erik C,Robinson Mark D,Krieg Carsten,Redmond William L,Egan Jack O,Rhode Peter R,Jeng Emily K,Rock Amy D,Wong Hing C,Rubinstein Mark P

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

2. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057);Horn;J Clin Oncol,2017

3. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016

4. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study;Langer;Lancet Oncol,2016

5. Overall survival with combined nivolumab and ipilimumab in advanced melanoma;Wolchok;N Engl J Med,2017

Cited by 327 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Macrophage crosstalk and therapies: Between tumor cells and immune cells;International Immunopharmacology;2024-11

2. The JAK-STAT pathway: from structural biology to cytokine engineering;Signal Transduction and Targeted Therapy;2024-08-21

3. Advancements and challenges in immunocytokines: A new arsenal against cancer;Acta Pharmaceutica Sinica B;2024-08

4. Advancing non-small cell lung cancer treatment: the power of combination immunotherapies;Frontiers in Immunology;2024-07-02

5. Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis;Cancer Immunology, Immunotherapy;2024-06-04